Search results
Genetics Played Role in Blood Clots Linked to COVID-19 Shots
Time Magazine· 19 minutes agoRare but deadly blood clots tied to Johnson & Johnson and AstraZeneca Plc’s Covid-19 shots were...
How to Get Prescribed Ozempic For Weight Loss
MediaFeed via AOL· 6 days agoGenetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to shed excess pounds, you...
Myriad Genetics CEO Paul J. Diaz sells shares worth over $5.7 million By Investing.com
Investing.com· 7 hours agoPaul J. Diaz, the President and CEO of Myriad Genetics Inc. (NASDAQ:MYGN), has recently sold a...
Myriad Genetics director Lee Nisley sells $156,860 in company stock By Investing.com
Investing.com· 7 hours agoFollowing the sale, Nisley still retains a significant stake in the company, owning 66,650 shares of...
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter...
Simply Wall St. via Yahoo Finance· 5 days agoAs you might know, Myriad Genetics, Inc. (NASDAQ:MYGN) just kicked off its latest first-quarter...
Earnings call: SOPHiA GENETICS sees 13% revenue growth in Q1 2024 By Investing.com
Investing.com· 3 days agoEarnings call: SOPHiA GENETICS sees 13% revenue growth in Q1 2024
Gypsy-Rose Blanchard Shares Post-Nose Job Pics and Recovery Update: 'The Boogers Are Insane'
People Magazine· 4 hours agoGypsy-Rose Blanchard is proudly sharing her recovery journey after undergoing a rhinoplasty in...
Ambry Genetics, Pacific Biosciences to Sequence up to 7K Human Genomes for Rare Disease Study
GenomeWeb News· 10 hours agoAmbry Genetics and Pacific Biosciences said Wednesday that they will sequence up to 7,0000 human whole genomes over three years using long-read technology as part of a National ...
Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 7 days agoMyriad Genetics (NASDAQ:MYGN) First Quarter 2024 Results Key Financial Results Revenue: US$202.2m...
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $24.86 Consensus Target Price from Analysts
ETF DAILY NEWS· 2 days agoMyriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock ...